GPCR vs URGN: stock comparison and AI forecast
Structure Therapeutics Inc. (GPCR) and Urogen Pharma Ltd. (URGN) compared on price performance, valuation, profitability and the daily AI forecast. · Alpha · vs market
Share
GPCR Structure Therapeutics Inc.
- Market Cap
- $1.40B
- P/E Ratio
- –
- Size
- small-cap
- AI Forecast
URGN Urogen Pharma Ltd.
- Price
- $25.73 -2.0% · 6M
- Market Cap
- $1.26B
- P/E Ratio
- –
- Size
- small-cap
- AI Forecast
Which one does the AI model favor?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
Key facts
- GPCR is 1.1 times larger than URGN by market capitalization ($1.40B against $1.26B).
- Both companies share the SEC industry classification Pharmaceutical Preparations.
Fundamentals side by side
Trailing twelve months.
Valuation & Market
| Metric | GPCR | URGN |
|---|---|---|
| Market Cap | $1.40B | $1.26B |
| P/B Ratio | 1.03x | – |
| EPS | $-0.66 | – |
| Book Value/Share | $18.52 | – |
| Revenue/Share | – | $5.12 |
| FCF/Share | $-3.07 | $-2.70 |
Profitability & Margins
| Metric | GPCR | URGN |
|---|---|---|
| ROA | – | -24.2% |
| ROIC | -19.0% | -15.6% |
| Gross Margin | – | 92.1% |
| Operating Margin | – | -12.4% |
| Net Margin | – | -26.3% |
| EBT Margin | – | -25.6% |
| Tax Rate | -0.3% | -2.5% |
Financial Health
| Metric | GPCR | URGN |
|---|---|---|
| Current Ratio | 20.75x | 3.40x |
| Quick Ratio | – | 3.06x |
| D/E Ratio | 0.05x | – |
| Financial Leverage | 1.05x | – |
| Interest Coverage | – | -18.7x |
| Working Capital | $1.31B | $178M |
Cash Flow
| Metric | GPCR | URGN |
|---|---|---|
| Operating Cash Flow | -$220M | -$132M |
| Free Cash Flow | -$224M | -$132M |
| Capital Spending | -$4M | -$200K |
| FCF/Sales | – | -52.8% |
| CapEx/Sales | – | 0.1% |
Operational Efficiency
| Metric | GPCR | URGN |
|---|---|---|
| Asset Turnover | – | 0.92x |
| Receivables Turnover | – | 2.1x |
| Inventory Turnover | – | 0.8x |
| Fixed Assets Turnover | – | 425.6x |
| Days Sales Outstanding | – | 171 days |
| Days Inventory | – | 466 days |
| Payables Period | – | 320 days |
| Cash Conversion Cycle | – | 317 days |
Income Statement
| Metric | GPCR | URGN |
|---|---|---|
| Total Revenue | – | $250M |
| Operating Income | -$258M | -$31M |
| Net Income | – | -$66M |
| R&D Expense | $294M | $73M |
| SG&A Expense | – | $186M |
| Cost of Goods Sold | – | $20M |
Dividend & Shareholder Information
| Metric | GPCR | URGN |
|---|---|---|
| Shares Outstanding | 73M | 49M |
GPCR vs URGN: stock comparison and AI forecast
Which is bigger, GPCR or URGN?
GPCR is 1.1 times larger than URGN by market capitalization ($1.40B against $1.26B).
Which one does Intratio's AI model rank higher, GPCR or URGN?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
More comparisons
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.